RHÖN-KLINIKUM AG | 11/06/2015

Interim Report for the Third Quarter: RHÖN-KLINIKUM AG Business Development as Planned, Second Share Repurchase Scheme Completed, New Departmental Responsibilities for the Management Board

  • 569,978 patients treated
  • Revenues amount to € 832.0 million
  • EBITDA stands at € 117.3 million
  • Outlook for 2015 remains unchanged: revenues between € 1.08 billion and € 1.12 billion, EBITDA between € 145 million and € 155 million

RHÖN-KLINIKUM AG’s operative business progressed as planned in the first nine months of the current financial year. A total of 569,978 patients were treated in the company’s hospitals during this period. Revenues for the period from January up to and including September amounted to € 832.0 million and earnings before interest, taxes, depreciation and amortisation (EBITDA) stood at € 117.3 million. These financial figures are not directly comparable with those of previous years due to the sale of a total of 43 facilities which was completed during last financial year 2014.

Successful Completion of Second Share Repurchase Scheme

The second share repurchase scheme ended on 8th October 2015. The public purchase offer was accepted for a total of 6,519,390 RHÖN KLINIKUM shares at a share price of € 25.54 which corresponds to approx. 9 % of the total share capital issued on the cut-off date and a volume of approx. € 167 million. With its new financial structure the corporate group can now embrace more purposefully the requirements of resource management orientated to capital costs and is therefore in a better position to be able to take advantage of business opportunities for further development.

Larger Board of Management, Modified Departmental Responsibilities and Standardised Contractual Terms

The company’s Board of Management will be enlarged with effect from 1st January 2016. Prof. Dr. Bernd Griewing, spokesperson for the Medical Board and Medical Director of the Neurological Clinic in Bad Neustadt, has been appointed to the executive body by the Supervisory Board as the Chief Medical Officer (CMO) alongside Dr. Martin Siebert (CEO), Jens-Peter Neumann (CFO) and Martin Menger (COO). The departmental responsibilities of the Board of Management have also been modified and the terms of the service agreements of the Board of Management standardised; all the members will now receive a five-year agreement, each starting on 1st January 2016.


We continue to expect revenues of € 1.08 billion to € 1.12 billion and EBITDA of between € 145 million and € 155 million for 2015, the first full financial year with the new portfolio structure. As in previous years one-off effects will continue to influence the corporate results during this financial year as well. These positive and negative special influences will occur during the entire financial year 2015, their size is a low two-digit million figure and they will partially cancel each other out. “We are continuing to press ahead with the extensive implementation of our corporate strategy with targeted investments in the building structures and medical equipment of our hospitals, systematically linking medicine and nursing to each other and also realising synergies,” CEO Dr. Martin Siebert said. “Our focus on healthcare which is orientated to maximum medical care and has a direct link to universities is also reflected in the new structure of the Board of Management: with a larger Board and modified departmental responsibilities we have now created the preconditions for consistent further development of the larger medical concepts of the future, such as e health, ensuring high-quality medical care in rural areas and extending medical networks to provide excellent healthcare services further afield. This will benefit our patients, employees and shareholders alike,” Siebert continued.


Your Contact Persons:
Achim Struchholz
Head of Corporate Communication
Schlossplatz 19
7616 Bad Neustadt / Saale
Telephone: + 49 - 9771 65-1327
Facsimile: + 49 - 9771 65-1820
E-Mail: kommunikation(at)

Dr. Kai G. Klinger
Head of Investor Relations & Group Financing
Schlossplatz 19
7616 Bad Neustadt / Saale
Telephone: + 49 - 9771 65-1318
Facsimile: + 49 - 9771 99-1736
E-Mail: ir(at)